Spostitul Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and Trademark Office

Attorney's Docket No. 07039-163003

Application No. 10/667,625

formation Disclosure Statement

by Applicant (Use several sheets if necessary)

Applicant Nalini M. Rajamannan

Filing Date September 22, 2003

Group Art Unit

1636

	U.S. Patent Documents						
Examiner Initial	Desig. ID	Patent Number	Issue Date	Patentee	Class	Subclass	Filing Date If Appropriate
QN	AA	4,477,930	10/23/84	Totten et al.		Oubolass	ii Appropriate
	AB	4,683,195	07/28/87	Mullis et al.		 	7
	AC	4,762,842	08/09/88	Cohen et al.		 	
	AD	4,873,191	10/10/89	Wagner et al.		 	/
	AE	5,175,384	12/29/92	Krimpenfort et al.			- / -
	AF	5,175,385	12/29/92	Wagner et al.			
	AG	5,580,859	12/03/96	Felgner et al.			
	AH	5,589,466	12/31/96	Felgner et al.			/
	AI	5,650,447	07/22/97	Keefer et al.			/
	AJ	5,797,870	08/25/98	March et al.		/	
	AK	5,855,620	01/05/99	Bishopric et al.		-/-	
	AL	5,880,102	03/09/99	George et al.		/ - 	
	AM	5,928,281	07/27/99	Huynh et al.			
	AN	5,935,163	08/10/99	Gabbay			
	AO	6,060,640	05/09/00	Pauley et al.			
	AP	6,087,479	07/11/00	Stamler et al.	1 / 1		
an	AQ	6,193,749	02/27/01	Schroeder et al.	1-/-		

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Trans	slation
	AR			· disit sinos	Class	Subclass	Yes	No

	Other D	ocuments (include Author, Title, Date, and Place of Publication)
Examiner Initial	Desig. ID	Document
QN	AS	GenBank Accession No. P29476
	AT	GenBank Accession No. 742990
	AU	GenBank Accession No. AAA36364
QN	ΑV	GenBank Accession No. AAA36376

Examiner Signature

Date Considered

EXAMINER: Initials clasion considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

		·	<u> </u>
Substitute Form PTO-1449 (Modified)		Attorney's Docket No. 07039-163003	Application No. 10/667,625
by A	sclosure Statement Applicant sheets if necessary)	Applicant Nalini M. Rajamannan	
(37 CFR §1.98(b))	• •	Filing Date September 22, 2003	Group Art Unit 1645 1636

	Other D	Oocuments (include Author, Title, Date, and Place of Publication)
Examiner Initial	Desig. ID	
QN	AW	GenBank Accession No. AAB22708
1	AX	GenBank Accession No. AAB39539
	AY	GenBank Accession No. AAB49040
	AZ	GenBank Accession No. AAB60654
	AAA	GenBank Accession No. AAB68663
	ABB	GenBank Accession No. AC52766
	ACC	GenBank Accession No. AAC52782
	ADD	GenBank Accession No. AAC61262
	AEE	GenBank Accession No. AAD29751
	AFF	GenBank Accession No. AAD29752
	AGG	GenBank Accession No. AAD39340
	АНН	GenBank Accession No. BAA05652
	AII	GenBank Accession No. CAA53950
	AJJ	GenBank Accession No. D26607
	AKK	GenBank Accession No. 145946
	ALL	GenBank Accession No. M93718
	AMM	GenBank Accession No. P29473
	ANN	
-++	AOO	GenBank Accession No. P29474
	APP	GenBank Accession No. P29475
		GenBank Accession No. P29477
		GenBank Accession No. P35228
		GenBank Accession No. Q06518
		GenBank Accession No. Q62600
		GenBank Accession No. Q90703
	AUU	Angell et al., "Durability of the viable aortic allograft," J. Thorac. Cardiovasc. Surg., 1989, 98:48-56
		Berkner et al., "Generation of adenovirus by transfection of plasmids," Nucleic Acids Res., 1983, 11:6003-6020
an	AWW	Braunwald, "Aortic Stenosis - Etiology and Pathology," <u>Heart Disease</u> , 1992, 4th Edition, pp. 1035-

Examiner Signature	Date Considered
EXAMINER: Initials citation considered braw line through citation if no next communication to applican).	10/28/04
next communication to applican).	this contornalities and not considered. Include copy of this form with

			5.100t <u>5</u> 01 <u>4</u>
Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-163003	Application No. 10/667,625
Information Disclosure Statement by Applicant (Use several sheets if necessary)		Applicant Nalini M. Rajamannan	
(37 CFR §1.98(b))	• •	Filing Date September 22, 2003	Group Art Unit 1645 1636

	Other [Oocuments (include Author, Title, Date, and Place of Publication)
Examiner Initial	Desig. ID	Document
QN	AXX	Clancy et al., "Outside-In Signaling in the Chondrocyte. Nitric Oxide Disrupts Fibronectin-induce Assembly of a Subplasmalemmal Actin/Rho A/Focal Adhesion Kinase Signaling Complex," J. Cli Invest., 1997, 100(7):1789-1796
	AYY	Cooke and Dzau, "Nitric Oxide Synthase: Role in the Genesis of Vascular Disease," Annu. Rev. Med., 1997, 48:489-509
	AZZ	Dayan et al., "Are the polarization colors of Picrosirius red-stained collagen determined only by the diameter of the fibers?" Histochemistry, 1989, 93:27-29
	AAAA	Dzau et al., "Fusigenic viral liposome for gene therapy in cardiovascular diseases," <u>Proc. Natl. Aca</u> Sci. USA, 1996, 93:11421-11425
	ABBB	Eck and Wilson, "Gene-based therapy," Goodman & Gillman's The Pharmacological Basis of Therapeutics, 1996, pp. 77-101
	ACCC	Ghosh-Choudhury and Graham, "Stable Transfer of a Mouse Dihydrofolate Reductase Gene Into A Deficient Cell Line Using Human Adenovirus Vector," <u>Biochem. Biophys. Res. Comm.</u> , 1987, 147:964-973
	ADDD	Gibbons and Dzau, "Molecular Therapies for Vascular Diseases," Science, 1996, 272(5262):689-693
	AEEE	Gluzman et al., "Helper-free Adenovirus Type-5 Vectors," <u>Eukaryotic Viral Vectors</u> , 1982, pp. 187
	AFFF	Gordon, "Transgenic Animals," Int'l. Rev. Cytol., 1989, 115:171-229
	AGGG	Gossler et al., "Transgenesis by means of blastocyst-derived embryonic stem cell lines," Proc. Natl. Acad. Sci. USA, 1986, 83:9065-9069
	АННН	Guillot et al., "Gene therapy in transplantation in the year 2000: moving towards clinical applications?" Gene Therapy, 2000, 7:14-19
	AIII	Hammer et al., "Production of transgenic rabbits, sheep and pigs by microinjection," Nature, 1985, 315:680-683
	AJJJ	Hernández-Perera et al., "Effects of the 3-Hydroxy-3-Methylglutaryl-CoA Reductase Inhibitors, Atorvastatin and Simvastatin, on the Expression of Endothelin-1 and Endothelial Nitric Oxide Synthase in Vascular Endothelial Cells," J. Clin. Invest., 1998, 101(12):2711-2719
	AKKK	Characteristics," J. Mol. Cell. Cardiol., 1987, 19:1185-1193
	ALLL	Krimpenfort et al., "Generation of Transgenic Dairy Cattle Using 'In Vitro' Embryo Production," Bio/Technology, 1991, 9:844-847
		Kullo et al., "Expression and Function of Recombinant Endothelial NO Synthase in Coronary Artery Smooth Muscle Cells," Arterioscler, Thromb. Vasc. Biol. 1997, 17:2405, 2412
		Synthase," Circulation, 2000, 101:2345-2348
	A000	Mann et al., "Cell Cycle Inhibition Preserves Endothelial Function in Genetically Engineered Rabbit Vein Grafts," J. Clin. Invest., 1997, 99(6):1295-1301
	APPP	McGrory et al., "A Simple Technique for the Rescue of Early Region I Mutations into Infectious Human Adenovirus Type 5," Virology, 19888, 163:614-617
20	A000	Mohler III et al., "Detection of Osteopontin in Calcified Human Aortic Valves," Arterio. Thromb. Vascul. Biol., 1997, 17(3):547-552

Examiner Signature	Date Considered
On Pine	10/28/01/
EXAMINER: Initials citation considered. Draw line through citation if next communication to applicant.	ot in conformance and not considered. Include copy of this form with
to applicant.	Substitute Disclosure Form (PTO-1449)

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 07039-163003	Application No. 10/667,625
by A	closure Statement	Applicant Nalini M. Rajamannan	
(Use several si (37 CFR §1.98(b))	neets if necessary)	Filing Date September 22, 2003	Group Art Unit 1645 1636

	Other D	Oocuments (include Author, Title, Date, and Place of Publication)
Examiner Initial	Desig. ID	
CiN	ARRR	Document Myers and Tanner, "Vascular Endothelial Cell Regulation of Extracellular Matrix Collagen: Role of Nitric Oxide," Arterio. Thromb. Vascul. Biol., 1998, 18(5):717-722
	ASSS	Ngo et al., "Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox," The Protein Folding Problem and Tertiary Structure Prediction, 1994, pp. 401, 405
	ATTT	allograft valves, with a note on chromosomal studies," <u>J. Thorac. Cardiovasc. Surg.</u> , 1987, 94(6):812-823
	AUUU	Onoue et al., "Expression and Function of Recombinant Endothelial Nitric Oxide Synthase Gene in Canine Basilar Artery After Experimental Subarachnoid Hemorrhage," Stroke: Journal of the American Heart Association, 1998, 29(9):1959-1965
	AVVV	Palmiter and Brinster, "Transgenic Mice," Cell, 1985, 41:343-345
	AWWW	
	AXXX	Rajamannan et al., "Macrophage conditioned media stimulates valvular subendothelial cell proliferation and matrix protein production," <u>Leukocyte-Endothelial Cell Interactions</u> , Page A614, Abstract No. 3542
	AYYY	Rizvi and Myers, "Nitric Oxide Modulates Basal and Endothelin-induced Coronary Artery Vascular Smooth Muscle Cell Proliferation and Collagen Levels," J. Mol. Cell. Cardiol., 1997, 29:1779-1789
	AZZZ	Peptide Hormones, 1976, pp. 1-7
	AAAAA	Schnieke et al., "Human Factor IX Transgenic Sheep Produced by Transfer of Nuclei from Transfected Fetal Fibroblasts." Science, 1997, 278-2130-2133
	ABBBB	Thompson et al., "Germ Line Transmission and Expression of a Corrected HPRT Gene Produced by Gene Targeting in Embryonic Stem Cells." Cell 1989, 56:313-321
	ACCCC	Arteries Without Endothelium." Arterio, Thromb Vascul Biol 1998 1888) 1221 1241
	ADDDD	Proc. Natl. Acad. Sci. USA, 1985, 82:6148-6152
	AEEEE	van Doren and Gluzman, "Efficient Transformation of Human Fibroblasts by Adenovirus-Simian Virus 40 Recombinants," Mol. Cell. Biol., 1984, 4:1653-1656
	AFFFF	von der Leyen et al., "Gene therapy inhibiting neointimal vascular lesion: In vivo transfer of endothelial cell nitric oxide synthase gene." Proc. Natl. Acad. Sci. USA, 1995, 92(4):1127, 1141
34	AGGGG	Wilmut et al., "Viable offspring derived from fetal and adult mammalian cells," Nature, 1997, 385:810-813

Examiner Signature	Date Considered
EXAMINED: Initials distribution applications of the state	10/28/04
next communication to applicant.	ot in conformance and not considered. Include copy of this form with